胆固醇、他汀类药物与痴呆症：心脏病专家应了解的内容。
Cholesterol, statins, and dementia: what the cardiologist should know.
作者信息
Wanamaker Brett L, Swiger Kristopher J, Blumenthal Roger S, Martin Seth S
机构信息
Department of Medicine, Division of Cardiology, The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University, Baltimore, Maryland.
出版信息
Clin Cardiol. 2015 Apr;38(4):243-50. doi: 10.1002/clc.22361. Epub 2015 Apr 13.
Abstract
Alzheimer dementia (AD) is an important clinical problem that appears to be closely tied to comorbid cardiovascular disease, making it a relevant topic for the clinical cardiologist. Determinants of cardiovascular health, especially midlife dyslipidemia, are associated with an increased risk of dementia based on molecular and epidemiologic data. Given the potential role of dyslipidemia in the development of dementia, statins have been investigated as potential therapeutic options to slow or prevent disease. This review discusses the role of dyslipidemia and other cardiovascular risk factors in the pathogenesis of AD, with a focus on the existing evidence for the use of statin medications in the treatment and prevention of AD from observational studies and randomized clinical trials. Clinical questions for the practicing cardiologist are addressed.
摘要
阿尔茨海默病性痴呆（AD）是一个重要的临床问题，似乎与合并的心血管疾病密切相关，这使其成为临床心脏病专家关注的相关话题。基于分子和流行病学数据，心血管健康的决定因素，尤其是中年血脂异常，与痴呆风险增加有关。鉴于血脂异常在痴呆症发生发展中的潜在作用，他汀类药物已被作为减缓或预防疾病的潜在治疗选择进行研究。本综述讨论了血脂异常和其他心血管危险因素在AD发病机制中的作用，重点关注观察性研究和随机临床试验中使用他汀类药物治疗和预防AD的现有证据。文中还探讨了临床心脏病专家面临的临床问题。
相似文献
1
Cholesterol, statins, and dementia: what the cardiologist should know.胆固醇、他汀类药物与痴呆症：心脏病专家应了解的内容。
Clin Cardiol. 2015 Apr;38(4):243-50. doi: 10.1002/clc.22361. Epub 2015 Apr 13.
2
Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.药物洞察：他汀类药物与依折麦布联合使用降低低密度脂蛋白胆固醇的作用
Nat Clin Pract Cardiovasc Med. 2006 Dec;3(12):664-72. doi: 10.1038/ncpcardio0711.
3
"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.“不打破就不修复”：对 ACCORD 血脂研究正反结果的评论。
Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.
4
The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges.他汀类药物治疗 HIV 血脂异常的安全性和有效性：迄今为止的证据和未来的挑战。
Expert Opin Pharmacother. 2012 Sep;13(13):1901-9. doi: 10.1517/14656566.2012.706604. Epub 2012 Jul 7.
5
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].[肾衰竭患者使用他汀类药物：慢性肾病和肾移植患者的疗效、耐受性及处方指南]
Presse Med. 2006 Feb;35(2 Pt 1):219-29. doi: 10.1016/s0755-4982(06)74557-2.
6
Who should receive a statin drug to lower cardiovascular risk? Does the drug and the dose of the drug matter?谁应该服用他汀类药物以降低心血管风险？药物及其剂量重要吗？
Vasc Health Risk Manag. 2006;2(4):441-6. doi: 10.2147/vhrm.2006.2.4.441.
7
Efficacy and safety of rosuvastatin in the management of dyslipidemia.瑞舒伐他汀治疗血脂异常的疗效与安全性。
Vasc Health Risk Manag. 2009;5(1):343-52. doi: 10.2147/vhrm.s3662. Epub 2009 Apr 8.
8
Emerging views of statin pleiotropy and cholesterol lowering.他汀类药物多效性和降胆固醇作用的新观点。
Cardiovasc Res. 2022 Jan 29;118(2):413-423. doi: 10.1093/cvr/cvab032.
9
New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.2 型糖尿病患者降脂治疗的新治疗选择。
Acta Diabetol. 2018 Mar;55(3):209-218. doi: 10.1007/s00592-017-1089-4. Epub 2017 Dec 19.
10
Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials.低密度脂蛋白胆固醇（LDL-C）、非高密度脂蛋白胆固醇（non-HDL-C）和载脂蛋白B（apoB）血浆水平变化与他汀类药物治疗降低风险的关系：一项随机试验的荟萃分析
J Am Heart Assoc. 2014 Apr 14;3(2):e000759. doi: 10.1161/JAHA.113.000759.
引用本文的文献
1
The Cross-Talk Between the Peripheral and Brain Cholesterol Metabolisms.外周与脑胆固醇代谢之间的相互作用
Curr Issues Mol Biol. 2025 Feb 11;47(2):115. doi: 10.3390/cimb47020115.
2
Lipidopathy disrupts peripheral and central amyloid clearance in Alzheimer's disease: Where are our knowledge.脂代谢异常破坏阿尔茨海默病的外周和中枢淀粉样蛋白清除：我们的认识到哪一步了。
IBRO Neurosci Rep. 2025 Jan 9;18:191-199. doi: 10.1016/j.ibneur.2025.01.004. eCollection 2025 Jun.
3
Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer's patients: A double-blind placebo-controlled randomized clinical trial.水飞蓟素和瑞舒伐他汀对血脂异常的阿尔茨海默病患者淀粉样蛋白携带者水平的影响：一项双盲安慰剂对照随机临床试验。
IBRO Neurosci Rep. 2024 Jul 20;17:108-121. doi: 10.1016/j.ibneur.2024.07.002. eCollection 2024 Dec.
4
Lipids and lipoproteins may play a role in the neuropathology of Alzheimer's disease.脂质和脂蛋白可能在阿尔茨海默病的神经病理学中发挥作用。
Front Neurosci. 2023 Nov 16;17:1275932. doi: 10.3389/fnins.2023.1275932. eCollection 2023.
5
Effects of a physical exercise or motor activity protocol on cognitive function, lipid profile, and BDNF levels in older adults with mild cognitive impairment.一项针对轻中度认知障碍老年人的身体运动或运动活动方案对认知功能、血脂谱和脑源性神经营养因子水平的影响。
Mol Cell Biochem. 2024 Mar;479(3):499-509. doi: 10.1007/s11010-023-04733-z. Epub 2023 Apr 26.
6
Is type 2 diabetes associated dementia a microvascular early-Alzheimer's phenotype induced by aberrations in the peripheral metabolism of lipoprotein-amyloid?2 型糖尿病相关痴呆是否为脂蛋白淀粉样蛋白外周代谢异常引起的微血管性早老性痴呆表型？
Front Endocrinol (Lausanne). 2023 Feb 16;14:1127481. doi: 10.3389/fendo.2023.1127481. eCollection 2023.
7
Targeting Alzheimer's Disease: The Critical Crosstalk between the Liver and Brain.靶向阿尔茨海默病：肝脏与大脑的关键串扰。
Nutrients. 2022 Oct 14;14(20):4298. doi: 10.3390/nu14204298.
8
BACE1: More than just a β-secretase.BACE1：不只是β-分泌酶。
Obes Rev. 2022 Jul;23(7):e13430. doi: 10.1111/obr.13430. Epub 2022 Feb 4.
9
Recent Neurotherapeutic Strategies to Promote Healthy Brain Aging: Are we there yet?促进大脑健康衰老的最新神经治疗策略：我们做到了吗？
Aging Dis. 2022 Feb 1;13(1):175-214. doi: 10.14336/AD.2021.0705. eCollection 2022 Feb.
10
The Emerging Role of Metabolism in Brain-Heart Axis: New Challenge for the Therapy and Prevention of Alzheimer Disease. May Thioredoxin Interacting Protein (TXNIP) Play a Role?代谢在脑心轴中的新兴作用：阿尔茨海默病治疗和预防的新挑战。硫氧还蛋白相互作用蛋白 (TXNIP) 是否发挥作用？
Biomolecules. 2021 Nov 8;11(11):1652. doi: 10.3390/biom11111652.
本文引用的文献
1
Evolocumab in hyperlipidemia.依洛尤单抗治疗高脂血症
N Engl J Med. 2014 Aug 28;371(9):877-8. doi: 10.1056/NEJMc1408237.
2
Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study.中年高血压与20年认知变化：社区动脉粥样硬化风险神经认知研究
JAMA Neurol. 2014 Oct;71(10):1218-27. doi: 10.1001/jamaneurol.2014.1646.
3
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.依洛尤单抗或依折麦布联合中等强度或高强度他汀类药物治疗对高胆固醇血症患者 LDL-C 降低的影响：LAPLACE-2 随机临床试验。
JAMA. 2014 May 14;311(18):1870-82. doi: 10.1001/jama.2014.4030.
4
Arterial stiffness and β-amyloid progression in nondemented elderly adults.非痴呆老年人群动脉僵硬度与β-淀粉样蛋白进展。
JAMA Neurol. 2014 May;71(5):562-8. doi: 10.1001/jamaneurol.2014.186.
5
Does the evidence say a 4-point change in ADAS-cog score is clinically significant?现有证据是否表明阿尔茨海默病协作研究-认知量表（ADAS-cog）评分4分的变化具有临床意义？
Alzheimers Dement. 2014 May;10(3):416-7. doi: 10.1016/j.jalz.2013.12.017. Epub 2014 Mar 12.
6
Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis.胆固醇是阿尔茨海默病的致病因素：一个有争议的假说。
J Neurochem. 2014 May;129(4):559-72. doi: 10.1111/jnc.12637. Epub 2014 Jan 2.
7
Statins and cognitive function: a systematic review.他汀类药物与认知功能：系统评价。
Ann Intern Med. 2013 Nov 19;159(10):688-97. doi: 10.7326/0003-4819-159-10-201311190-00007.
8
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2013年美国心脏病学会/美国心脏协会心血管风险评估指南：美国心脏病学会/美国心脏协会实践指南工作组报告
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2935-2959. doi: 10.1016/j.jacc.2013.11.005. Epub 2013 Nov 12.
9
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2013年美国心脏病学会/美国心脏协会成人降低动脉粥样硬化性心血管风险的血胆固醇治疗指南：美国心脏病学会/美国心脏协会实践指南工作组报告
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. Epub 2013 Nov 12.
10
Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult.为何阿尔茨海默病试验会失败：清除可溶性寡聚β淀粉样蛋白至关重要，但却存在不一致性且困难重重。
Neurobiol Aging. 2014 May;35(5):969-74. doi: 10.1016/j.neurobiolaging.2013.10.085. Epub 2013 Oct 19.
Zotero 插件